Advanced

History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response.

Huzell, Louise; Persson, Mia; Simonsson, Maria LU ; Markkula, Andrea LU ; Ingvar, Christian LU ; Rose, Carsten LU and Jernström, Helena LU (2015) In Breast Cancer Research and Treatment 149(2). p.505-515
Abstract
The purpose was to study oral contraceptive (OC) use in relation to breast cancer events and endocrine treatment response in a prospective population-based cohort, because it is unclear whether history of OC use impacts on prognosis in breast cancer patients. Between 2002 and 2011, 994 primary breast cancer patients without preoperative treatment were enrolled in Lund, Sweden and followed until December 2012. History of OC use was obtained from preoperative questionnaires. Tumor characteristics, clinical data, and date of death were obtained from pathology reports, patient charts, and population registries. Among the 948 patients with invasive cancer and no metastasis detected on the post-operative screen, 74 % had ever used OCs. Patients... (More)
The purpose was to study oral contraceptive (OC) use in relation to breast cancer events and endocrine treatment response in a prospective population-based cohort, because it is unclear whether history of OC use impacts on prognosis in breast cancer patients. Between 2002 and 2011, 994 primary breast cancer patients without preoperative treatment were enrolled in Lund, Sweden and followed until December 2012. History of OC use was obtained from preoperative questionnaires. Tumor characteristics, clinical data, and date of death were obtained from pathology reports, patient charts, and population registries. Among the 948 patients with invasive cancer and no metastasis detected on the post-operative screen, 74 % had ever used OCs. Patients were followed for up to nine years (median follow-up 3 years), and 100 breast cancer events were recorded. Ever OC use was not associated with prognosis, irrespective of duration. However, any OC use before age 20 was associated with a threefold increased risk for breast cancer events in patients <50 years but not in patients ≥50 years (P interaction = 0.009). In patients ≥50 years with estrogen receptor positive tumors, previous OC use at any age was associated with a significantly decreased risk of breast cancer events among patients who received aromatase inhibitors compared to patients who never used OCs (adjusted HR 0.37: 95 % CI 0.15-0.87). OC use was not associated with tamoxifen-response. If confirmed, history of OC use may yield valuable prognostic and treatment predictive information in addition to currently used criteria. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Breast Cancer Research and Treatment
volume
149
issue
2
pages
505 - 515
publisher
Springer
external identifiers
  • pmid:25556354
  • wos:000348976600019
  • scopus:84925491756
ISSN
1573-7217
DOI
10.1007/s10549-014-3252-8
language
English
LU publication?
yes
id
b8c61f5e-14cd-49da-b782-1024675b4651 (old id 5041474)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25556354?dopt=Abstract
date added to LUP
2015-02-02 17:10:30
date last changed
2017-09-24 03:03:57
@article{b8c61f5e-14cd-49da-b782-1024675b4651,
  abstract     = {The purpose was to study oral contraceptive (OC) use in relation to breast cancer events and endocrine treatment response in a prospective population-based cohort, because it is unclear whether history of OC use impacts on prognosis in breast cancer patients. Between 2002 and 2011, 994 primary breast cancer patients without preoperative treatment were enrolled in Lund, Sweden and followed until December 2012. History of OC use was obtained from preoperative questionnaires. Tumor characteristics, clinical data, and date of death were obtained from pathology reports, patient charts, and population registries. Among the 948 patients with invasive cancer and no metastasis detected on the post-operative screen, 74 % had ever used OCs. Patients were followed for up to nine years (median follow-up 3 years), and 100 breast cancer events were recorded. Ever OC use was not associated with prognosis, irrespective of duration. However, any OC use before age 20 was associated with a threefold increased risk for breast cancer events in patients &lt;50 years but not in patients ≥50 years (P interaction = 0.009). In patients ≥50 years with estrogen receptor positive tumors, previous OC use at any age was associated with a significantly decreased risk of breast cancer events among patients who received aromatase inhibitors compared to patients who never used OCs (adjusted HR 0.37: 95 % CI 0.15-0.87). OC use was not associated with tamoxifen-response. If confirmed, history of OC use may yield valuable prognostic and treatment predictive information in addition to currently used criteria.},
  author       = {Huzell, Louise and Persson, Mia and Simonsson, Maria and Markkula, Andrea and Ingvar, Christian and Rose, Carsten and Jernström, Helena},
  issn         = {1573-7217},
  language     = {eng},
  number       = {2},
  pages        = {505--515},
  publisher    = {Springer},
  series       = {Breast Cancer Research and Treatment},
  title        = {History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response.},
  url          = {http://dx.doi.org/10.1007/s10549-014-3252-8},
  volume       = {149},
  year         = {2015},
}